Therapeutic Management of COVID-19 in a Pediatric Patient with Neurodegenerative CLN2 Disease and ICV—Enzyme Replacement Therapy: A Case Report

Abstract

The 12 years old male patient presented here suffers from neuronal ceroid lipofuscinoses 2 (CLN2) (MIM# 204500) and receives intracerebroventricular enzyme replacement therapy (ICV-ERT) every 14 days. After the emergence of the coronavirus disease 2019 (COVID-19) pandemic, routine care of children and adolescents with rare chronic diseases has become challenging. Although, in general, children do not develop severe COVID-19, when severe acute respiratory syndrome coronavirus 2 infection was detected by polymerase chain reaction-screening examination in our CLN2 patient before hospital admission for ICV-ERT, he was regarded to be at risk. Upon diagnosis, the patient developed respiratory deterioration symptoms and was admitted to our pediatric intensive care unit to receive oxygen, remdesivir, and steroids. As far as we know, this is the first CLN2 patient receiving intraventricular enzyme therapy with COVID-19 who required intensive care treatment and specific therapy.

Keywords

CLN2 disease - SARS-CoV-2 - respiratory symptom - COVID-19

Author Contributions

S.A., P.D., C.U.E., A.S., C.S., and D.S. contributed to clinical medical support and M.C., J.H., J.K-M.K., and R.K. contributed to diagnostic and therapeutic support.

Ethical Approval and Patient Consent

The parent has given written consent to the publication of the case.

Publikationsverlauf

Eingereicht: 29. Dezember 2021

Angenommen: 17. März 2022

Artikel online veröffentlicht:
17. Juli 2022

• References

• 1 Dong Y, Mo X, Hu Y. et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020; 145 (06) e20200702
• 2 Götzinger F, Santiago-García B, Noguera-Julián A. et al; ptbnet COVID-19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020; 4 (09) 653-661
• 3 Kousi M, Lehesjoki AE, Mole SE. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat 2012; 33 (01) 42-63
• 4 Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta 2015; 1852 (10 Pt B): 2237-2241
• 5 Schulz A, Ajayi T, Specchio N. et al; CLN2 Study Group. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med 2018; 378 (20) 1898-1907
• 6 Cohen-Pfeffer JL, Gururangan S, Lester T. et al. Intracerebroventricular delivery as a safe, long-term route of drug administration. Pediatr Neurol 2017; 67: 23-35
• 7 Slavc I, Cohen-Pfeffer JL, Gururangan S. et al. Best practices for the use of intracerebroventricular drug delivery devices. Mol Genet Metab 2018; 124 (03) 184-188
• 8 Kanne JP, Bai H, Bernheim A. et al. COVID-19 imaging: what we know now and what remains unknown. Radiology 2021; 299 (03) E262-E279
• 9 Méndez-Echevarría A, Pérez-Martínez A, Gonzalez Del ValleL. et al. Compassionate use of remdesivir in children with COVID-19. Eur J Pediatr 2021; 180 (04) 1317-1322
• 10 Goldman DL, Aldrich ML, Hagmann SHF. et al. Compassionate use of remdesivir in children with severe COVID-19. Pediatrics 2021; 147 (05) e2020047803
• 11 Eleftheriou I, Liaska M, Krepis P. et al. Sinus bradycardia in children treated with remdesivir for COVID-19. Pediatr Infect Dis J 2021; 40 (09) e356
• 12 Rietdorf K, Coode EE, Schulz A, Wibbeler E, Bootman MD, Ostergaard JR. Cardiac pathology in neuronal ceroid lipofuscinoses (NCL): More than a mere co-morbidity. Biochim Biophys Acta Mol Basis Dis 2020; 1866 (09) 165643
• 13 Moll-Khosrawi P. The CLN3 (Batten) Disease: a description of the clinical phenotype in 25 CLN3 patients with an identical genotype, with special focus on cardiological findings . Dissertation to obtain the degree of doctor of medicine; Medical Faculty University of Hamburg, 2017
• 14 Boulad F, Kamboj M, Bouvier N, Mauguen A, Kung AL. COVID-19 in children with cancer in New York City. JAMA Oncol 2020; 6 (09) 1459-1460
• 15 Schwierzeck V. et al. First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric dialysis unit. Clin Infect Dis. 2021; 72 (02) 265-270